GAD-7 & PHQ-9
The Generalized Anxiety Disorder (GAD-7) & Patient Health Questionnaire (PHQ-9). This survey asks you about how you are feeling and how you are coping from day to day since your injury. You must answer ALL questions as best you can.
Over the last 2 weeks, how often have you been bothered by the following problems?
Please answer every question by tapping the number from 0 to 3 to show how much this problem bothers you, (0 - not at all, 1 - several days a week, 2 - more than half of the days in a week or 3- almost every day). You must answer ALL questions as best you can.
GAD-7 Anxiety Severity Interpretation
Scoring key: 0-5 minimal/mild anxiety, 6-10 moderate anxiety, 11-15 moderate/severe anxiety, 15-21 severe anxiety.
The score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of “not at all,” “several days,” “more than half the days,” and “nearly every day,” respectively. GAD-7 total score for the seven items ranges from 0 to 21.
PHQ-9 Depression Severity Interpretation
Scoring key: 0-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderate/severe depression, 20-27 severe depression.
The score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of “not at all,” “several days,” “more than half the days,” and “nearly every day,” respectively. PHQ-9 total score for the nine items ranges from 0 to 27.
Discussion
The triad of somatization, anxiety and depression (SAD) are the most common mental disorders. SAD frequently interferes with activities of daily living and interpersonal interactions and is responsible for significant loss of productivity. Detecting SAD and initiating treatment is medically necessary and monitoring clinical response to therapy is crucial. The Patient Health Questionnaire 9 (PHQ-9) and Generalized Anxiety Disorder 7 (GAD-7) are commonly used patient reported outcome scales (PROS) that assess mental disorders such as SAD. PROS are efficient tools for monitoring response to treatment. Measurement-based care has been shown to enhance SAD treatment response. The PHQ-9 and GAD-7 will be administered periodically and utilized in this case to monitor the patients progress and adjust treatment as necessary.
Aric Hausknecht, MD
Stacey Jaff, MD
Jonathan Kent, PhD
Lee Briones, CSW